ABBV logo AbbVie +
AbbVie
+

AbbVie (ABBV) Business News

Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
3:45 PM | Tuesday | Jun 30, 2026 Fool - Investing News

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

News Thumbnail
1:35 PM | Tuesday | Jun 30, 2026 Zacks Investment Research

What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?

News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026 Proactive Investors

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
12:31 PM | Tuesday | Jun 30, 2026 Benzinga

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

News Thumbnail
10:01 AM | Tuesday | Jun 30, 2026 Zacks Investment Research

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

News Thumbnail
8:19 AM | Tuesday | Jun 30, 2026 Proactive Investors - Finance

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026 Proactive Investors

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
12:31 PM | Tuesday | Jun 30, 2026 Benzinga

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

News Thumbnail
10:01 AM | Tuesday | Jun 30, 2026 Zacks Investment Research

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

News Thumbnail
12:25 PM | Monday | Jun 29, 2026 Zacks Investment Research

ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases

News Thumbnail
12:11 PM | Monday | Jun 29, 2026 Zacks Investment Research

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

News Thumbnail
11:43 AM | Monday | Jun 29, 2026 Fool - Investing News

3 No-Brainer Dividend Stocks to Buy Right Now

News Thumbnail
11:21 AM | Monday | Jun 29, 2026 The Motley Fool

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

News Thumbnail
11:21 AM | Monday | Jun 29, 2026 Zacks Investment Research

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?

News Thumbnail
4:00 AM | Monday | Jun 29, 2026 GuruFocus

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

News Thumbnail
3:10 AM | Monday | Jun 29, 2026 PRNewsWire

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

News Thumbnail

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

Fool - Investing News

3:45 PM | Tuesday | Jun 30, 2026

news photo
Loading...

AbbVie knows how to plan ahead.

Read full article redirect
3:45 PM | Tuesday | Jun 30, 2026

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

Fool - Investing News

AbbVie knows how to plan ahead.

Read full article arrow
News Thumbnail
1:35 PM | Tuesday | Jun 30, 2026

What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?

Zacks Investment Research

ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.

Read full article arrow
News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Read full article arrow
News Thumbnail
12:31 PM | Tuesday | Jun 30, 2026

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Benzinga

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.

Read full article arrow
News Thumbnail
10:01 AM | Tuesday | Jun 30, 2026

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
8:19 AM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors - Finance

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

Read full article arrow
News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Read full article arrow
News Thumbnail
12:31 PM | Tuesday | Jun 30, 2026

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Benzinga

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.

Read full article arrow
News Thumbnail
10:01 AM | Tuesday | Jun 30, 2026

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
12:25 PM | Monday | Jun 29, 2026

ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases

Zacks Investment Research

AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.

Read full article arrow
News Thumbnail
12:11 PM | Monday | Jun 29, 2026

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

Zacks Investment Research

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

Read full article arrow
News Thumbnail
11:43 AM | Monday | Jun 29, 2026

3 No-Brainer Dividend Stocks to Buy Right Now

Fool - Investing News

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Read full article arrow
News Thumbnail
11:21 AM | Monday | Jun 29, 2026

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

The Motley Fool

AbbVie has outperformed the market this year, but its valuation remains modest. The company recently announced the acquisition of Apogee Therapeutics, further diversifying its operations.

Read full article arrow
News Thumbnail
11:21 AM | Monday | Jun 29, 2026

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?

Zacks Investment Research

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Read full article arrow
News Thumbnail
4:00 AM | Monday | Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

GuruFocus

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Read full article arrow
News Thumbnail
3:10 AM | Monday | Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

PRNewsWire

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 24 1,2 Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24 1,2 NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA).

Read full article arrow
News Thumbnail